XPO1 inhibitors, when used in combination with the proteasome inhibitors (PI) bortezomib and carfilzomib, were found to synergistically kill multiple myeloma (MM) cells and when co-cultured with bone marrow stromal cells [5, 6]. This evidence concerns the gene XPO1 and plasma cell myeloma.